GLPBio

Urantide

Catalog No.: GC50138Purity:>98%
COASDSData Sheet
Urantide is a selective and competitive urotensin-II (UT) receptor antagonist, with the pKB value of 8.32.

Products are for research use only. Not for human use. We do not sell to patients.

Urantide
Cas No.: 669089-53-6
1 mgIn Stock
$111.00
1
5 mgIn Stock
$226.00
1
10 mgIn Stock
$323.00
1
25 mgIn Stock
$529.00
1
50 mgIn Stock
$749.00
1
100 mgIn Stock
$987.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Urantide is a selective and competitive urotensin-II (UT) receptor antagonist, with the pKB value of 8.32 [1]. Urantide can down-regulate the expression levels of UT and GPR14 in the liver and reduce the phosphorylation levels of Erk1/2 and JNK to prevent hepatic steatosis [2]. Urantide has been widely used to regulate the contraction and calcium release in the thoracic aorta of rats[3].

In vitro, Urantide (1μM) treatment for 48 hours significantly inhibited the urotensin II-stimulated proliferation of rat vascular smooth muscle cells (VSMCs) and induced cell cycle arrest[4]. Treatment with 1μM Urantide for 48 hours significantly reduced the expression of p-JAK2 and p-STAT3 proteins and the phenotypic transformation in rat VSMCs [5].

In vivo, Urantide treatment via intraperitoneal injection at a dose of 30μg/kg three times within 2 weeks significantly alleviated myocardial injury in rats with atherosclerosis[6]. Intraperitoneal injection of 10μg/kg/day dose of Urantide for 3 weeks significantly alleviated the increase in pulmonary arterial hypertension (PAH) induced by monocrotaline in rats and improved the structure and function of the right ventricle[7].

References:
[1] Carotenuto A, Auriemma L, Merlino F, et al. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor[J]. Journal of Medicinal Chemistry, 2014, 57(14): 5965-5974.
[2] Cui H, Lin Y, Xie L, et al. Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway[J]. Molecular Medicine Reports, 2021, 23(4): 1-10.
[3] Camarda V, Song W, Marzola E, et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors[J]. European journal of pharmacology, 2004, 498(1-3): 83-86.
[4] Zhao J, Zhang S F, Shi Y, et al. Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J]. Bosnian Journal of Basic Medical Sciences, 2013, 13(2): 78.
[5] Wang T, Xie L, Bi H, et al. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway[J]. European Journal of Pharmacology, 2021, 902: 174037.
[6] Zhao J, Miao G, Wang T, et al. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway[J]. Life sciences, 2020, 262: 118551.
[7] Wang Y, Tian W, Xiu C, et al. Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model[J]. Clinical rheumatology, 2019, 38(1): 29-35.

Protocol

Cell experiment [1]:

Cell lines

Rat vascular smooth muscle cells

Preparation Method

Rat vascular smooth muscle cells were grown in DMEM medium with 10% (v/v) fetal bovine serum (FBS), 100μg/ml streptomycin, and 100U/ml penicillin at 37°C in 5% CO2/atmosphere. Cells were seeded at a density of 1×105cells/ml in the 96-well plates and allowed to adhere in a 5% CO2 incubator at 37°C overnight. The cells were treated with different concentrations of Urantide (0, 0.001, 0.01, 0.1, and 1μM) in the presence of 0.01μM UT for 48h. Cell viability was evaluated.

Reaction Conditions

0, 0.001, 0.01, 0.1, and 1μM; 24h

Applications

Urantide treatment significantly reduced UT-induced cell proliferation of rat vascular smooth muscle cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

Wistar rats

Preparation Method

Wistar rats (3-month-old; 180-200g) were housed singly in a standard environment with food and water ad libitum. The rats were randomly assigned to one of the two groups: the early-treatment group (n=30) and the late-treatment group (n=30). Then, rats in each group were divided into three subgroups: control group, MCT group, and Urantide group (n=10 per subgroup). A PAH rat model was induced by the subcutaneous injection of 50mg/kg monocrotaline in the monocrotaline and Urantide groups. One week after PAH model construction, the surviving rats (some rats died of pulmonary edema or pulmonary hemorrhage within 1 week of monocrotaline injection) were injected intraperitoneally with either Urantide (10μg/kg/day) or an equal amount of normal saline (NS) (n=8) for 3 weeks. The normal control rats (n =10) received an equal volume of 0.9% saline for 3 weeks. Ultrasonic cardiogram was monitored at week 4.

Dosage form

10μg/kg/day for 3 weeks; i.p.

Applications

Urantide treatment significantly improved the structure and function of right ventricle in rats with PAH.

References:
[1] Zhao J, Zhang S F, Shi Y, et al. Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J]. Bosnian Journal of Basic Medical Sciences, 2013, 13(2): 78.
[2] Wang Y, Tian W, Xiu C, et al. Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model[J]. Clinical rheumatology, 2019, 38(1): 29-35.

Chemical Properties

CAS No.
669089-53-6
SMILES
CC(C)[C@H](NC(=O)[C@@H]1CSSC(C)(C)[C@@H](NC(=O)[C@@H](N)CC(O)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N1)C(O)=O
Molecular Formula
C51H66N10O12S2
Molecular Weight
1075.26
Solubility
Soluble in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Urantide

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%